Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

Table 3 Adverse clinical events at week 48 n (%)

Event	Intensity	TDF ( n = 26)	LAM+ADV ( n = 27)	Total (n = 53)	P value
Adverse reactions		2 (7.70)	0	2 (3.57)	0.236
Digestive intolerance	moderate	1 (3.85)	0	1 (1.89)	1.000
Muscle pains	moderate	1 (3.85)	0	1 (1.89)	1.000
Adverse events		14 (53.85)	9 (37.5)	23 (43.40)	0.17
Common cold	mild	3 (11.54)	2 (7.41)	5 (9.43)	0.699
Headache	mild	1 (3.85)	1 (3.70)	2 (3.77)	1.000
Retrosternal oppression with heartburn	moderate	0	1 (3.70)	1 (1.89)	1.000
Otitis	mild	1 (3.85)	0	1 (1.89)	0.491
Molar extraction	mild	1 (3.85)	0	1 (1.89)	0.491
Right- and left-flank pain	mild	1 (3.85)	0	1 (1.89)	0.491
Vomiting	mild	1 (3.85)	0	1 (1.89)	0.491
Osteoarticular pain in hands	mild	0	1 (3.70)	1 (1.89)	1.000
Hypophosphatemia and hypomagnesemia	moderate	0	1 (3.70)	1 (1.89)	1.000
Renal colic	mild	1 (3.85)	0	1 (1.89)	0.491
Epigastric pain	mild	1 (3.85)	0	1 (1.89)	0.491
Back pain	mild	1 (3.85)	0	1 (1.89)	0.491
Chronic prostatitis	mild	0	1 (3.70)	1 (1.89)	1.000
Epidermoid carcinoma	moderate	1 (3.85)	0	1 (1.89)	0.491
Vertiginous syndrome	mild	0	1 (3.70)	1 (1.89)	1.000
Itching (eyes, nose and mouth)	mild	1 (3.85)	0	1 (1.89)	0.491
Vertigo	mild	0	1 (3.70)	1 (1.89)	1.000
Choluria	mild	1 (3.85)	0	1 (1.89)	0.491

ADV: Adefovir dipivoxil; LAM: Lamivudine; TDF: Tenofovir dipivoxil fumarate.